2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy?

By Christopher Gannatti, CFA, Global Head of Research Key Takeaways The biotechnology sector has not seen a sustained rally in 2024 despite initial optimism and ongoing progress. Sarepta Therapeutics’ Elevidys, a $3.2 million gene therapy for Duchenne muscular dystrophy, received expanded FDA approval in June 2024, with positive indications on insurance coverage being a key [...] The post 2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy? appeared first on ETF Trends .